Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827414 | 0.83 | TAAR1 (0.47) | TAAR1MMP8MMP1EPHX1CTSB | |
| SCHEMBL4818920 | 0.80 | TAAR1 (0.36) | TAAR1CTSCKCNH2CACNA1GCACNA1H | |
| SCHEMBL8298293 | 0.77 | CACNA1G (0.39) | TAAR1CTSCKCNH2CACNA1GCACNA1H | |
| SCHEMBL172091 | 0.77 | CTSC (0.42) | CTSCKCNH2EPHX1 | |
| SCHEMBL15601036 | 0.77 | MC4R (0.35) | TAAR1MMP8MMP1 | |
| SCHEMBL2061687 | 0.76 | GRM4 (0.45) | MMP8MMP1CTSCKCNH2EPHX1 | |
| SCHEMBL2061690 | 0.76 | GRM4 (0.45) | MMP8MMP1CTSCKCNH2EPHX1 | |
| SCHEMBL2061686 | 0.76 | GRM4 (0.45) | MMP8MMP1CTSCKCNH2EPHX1 | |
| SCHEMBL4826158 | 0.76 | CTSB (0.37) | CTSCKCNH2EPHX1CACNA1GCACNA1H | |
| SCHEMBL22778763 | 0.75 | TAAR1 (0.31) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | TAAR1 2307/4885MMP8 250/4885MMP1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.